Clinical Trials on Movement; Abnormal, Involuntary in Portugal

Total 63 results

Campus Neurológico Sénior

Completed

Immersive Virtual Reality for the Non-pharmacological Management of Parkinson's Disease

Parkinson Disease

Portugal
Centro Hospitalar de Lisboa Central

Not yet recruiting

Effectiveness of Botulinum Toxin in Freezing of Gate in Parkinson's Disease Walking in Parkinson's Disease.

Parkinson Disease | Botulinum Toxin | Freezing of Gate

Portugal
Campus Neurológico Sénior
Johns Hopkins University

Completed

The Feasibility and Efficacy of an Immersive Virtual Reality Software in Parkinson's Disease Patients

Parkinson Disease

Portugal
Campus Neurológico Sénior
University of Lisbon

Completed

Feasibility of the AHA Exergame System in Parkinson's Disease Patients

Parkinson Disease

Portugal
Albino Maia
Centro Hospitalar Lisboa Ocidental; Centro Hospitalar De São João, E.P.E.; Centro... and other collaborators

Recruiting

Deep Brain Stimulation-Induced Mania in Parkinson's Disease (BPD_DBS)

Parkinson Disease | Mania

Portugal
Bial - Portela C S.A.

Active, not recruiting

OpicApone Sleep dISorder (OASIS)

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg)

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Effect of Food on BIA 6-512 (Trans-resveratrol)

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Tolerability and Steady-state Pharmacokinetics of BIA 6-512

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients. (BIPARKII)

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg)

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide

Parkinson's Disease (PD)

Portugal
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin

Parkinson's Disease (PD)

Portugal
Bial - Portela C S.A.

Completed

A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067

Parkinson's Disease

Portugal, Romania, Ukraine
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide

Parkinson's Disease (PD)

Portugal
NeuraLight
European Clinical Research Infrastructure Network

Recruiting

Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease (PALOMA)

Parkinson Disease

United States, Switzerland, Portugal, United Kingdom, Spain
Juvantia Pharma Ltd
Santhera Pharmaceuticals

Unknown

Fipamezole in Neurogenic Orthostatic Hypotension (Foehn)

Parkinson's Disease | Multiple System Atrophy | Symptomatic Neurogenic Orthostatic Hypotension (NOH)

France, Portugal
Centre National de la Recherche Scientifique, France
Instituto de Medicina Molecular João Lobo Antunes

Unknown

Dysarthria in Parkinson's Disease: Lusophony vs. Francophony Comparison (FraLusoPark)

Disease Progression | Parkinson's Disease | Dysarthria | Speech | Medical Treatment | Cross-language

France, Portugal
Boston Scientific Corporation

Recruiting

Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET)

Essential Tremor

Germany, Korea, Republic of, Canada, Belgium, Hungary, Spain, Portugal, Italy
Abbott Products

Terminated

A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.

Advanced Stage Parkinson's Disease

Germany, Italy, Portugal
University College, London
Lund University; University Hospital, Bordeaux; Ludwig-Maximilians - University... and other collaborators

Completed

Care for Late Stage Parkinsonism (CLaSP)

Parkinson's Disease | Late Stage Parkinson's Disease

Netherlands, United Kingdom, Germany, France, Portugal, Sweden
Sanofi

Completed

Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease

Parkinson Disease

France, Canada, Germany, Netherlands, Portugal, Spain, Sweden, Tunisia, Denmark, Morocco, South Africa, Austria, United Kingdom
University Hospital, Lille
European Commission; ApoPharma

Completed

Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease (FAIRPARKII)

Parkinson Disease

Netherlands, Spain, France, Portugal, Czechia, United Kingdom, Austria, Germany
Ionis Pharmaceuticals, Inc.

Recruiting

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON) (HORIZON)

Multiple System Atrophy

Austria, Portugal, France, Germany, United Kingdom
Ipsen

Completed

Factors Influencing Response to One BoNT-A Injection Cycle in Subjects Suffering From Idiopathic Cervical Dystonia

Idiopathic Cervical Dystonia

Belgium, France, United Kingdom, Portugal, Germany, Australia, Czechia, Netherlands, Russian Federation
Ipsen

Completed

Study Comparing Short Term Efficacy of Dysport and Dysport NG to Placebo, and to Assess Efficacy and Safety of Dysport NG of Subjects With Cervical Dystonia

Cervical Dystonia

France, Belgium, Czechia, Australia, Poland, Portugal, Ukraine, Hungary, Russian Federation, Austria, Germany
Bial - Portela C S.A.

Active, not recruiting

eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs. (ADOPTION)

Parkinson Disease

Spain, Italy, Portugal, Germany, United Kingdom
Novartis

Completed

A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy

Parkinson's Disease

United States, France, Germany, Portugal, Netherlands, United Kingdom, Italy, Canada, Brazil
Ipsen

Completed

Phase IV-Cervical Dystonia-INTEREST IN CD2 (INTEREST_INCD2)

Cervical Dystonia

Korea, Republic of, Thailand, Belgium, Israel, Taiwan, Germany, Hungary, United States, Singapore, Slovenia, United Kingdom, Australia, Malaysia, Serbia, Estonia, Turkey, Italy, Poland, China, Sweden, Portugal, Algeria, Austria, Brazil, Czechi... and more
Genzyme, a Sanofi Company

Terminated

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation (MOVES-PD)

Parkinson's Disease

United States, Austria, Canada, France, Germany, Greece, Israel, Italy, Japan, Norway, Portugal, Singapore, Spain, Sweden, Taiwan, United Kingdom
Ultragenyx Pharmaceutical Inc

Active, not recruiting

Study of UX701 Gene Transfer for the Treatment of Wilson Disease

Wilson Disease

United States, Canada, Spain, Portugal, United Kingdom
EMD Serono

Completed

Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia

Parkinson's Disease | Dyskinesia

United States, France, Germany, Bulgaria, Belgium, Hungary, United Kingdom, Romania, Canada, Portugal, South Africa
Solvay Pharmaceuticals

Completed

An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients

Early Stage Parkinson's Disease

United States, Australia, Czech Republic, Estonia, Germany, India, Italy, Lithuania, Malaysia, Netherlands, Poland, Portugal, South Africa, Taiwan, Thailand
Bial R&D Investments, S.A.

Recruiting

Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD (ACTIVATE)

Parkinson's Disease

United States, Spain, France, Italy, Netherlands, United Kingdom, Germany, Canada, Poland, Portugal, Sweden
Eisai Limited

Completed

The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease

Poland, France, Spain, Germany, Hungary, Italy, Estonia, South Africa, Belgium, United Kingdom, Portugal, Austria, Czech Republic, Israel, Lithuania, Serbia, Sweden
NeuroDerm Ltd.

Active, not recruiting

Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)

Parkinson's Disease

United States, Israel, Spain, France, Russian Federation, Austria, Italy, Belgium, Czechia, Hungary, Netherlands, Poland, Portugal, Slovakia, Ukraine, United Kingdom
AbbVie
IQVIA, formerly Quintiles

Completed

Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease

Advanced Parkinson's Disease

United Kingdom, Czechia, United States, Australia, Canada, Israel, New Zealand, Poland, Portugal, Russian Federation, Thailand
Teva Branded Pharmaceutical Products R&D, Inc.
H. Lundbeck A/S; Teva Neuroscience, Inc.

Completed

ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects

Parkinson's Disease

United States, Argentina, Canada, France, Germany, Hungary, Israel, Italy, Netherlands, Portugal, Romania, Spain, United Kingdom
ACADIA Pharmaceuticals Inc.

Completed

A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Parkinson's Disease Psychosis

Spain, United States, Belgium, Austria, Serbia, Poland, Portugal, Italy, Sweden
AbbVie (prior sponsor, Abbott)
Quintiles, Inc.

Completed

Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease

Advanced Parkinson's Disease

United States, Australia, Canada, Czech Republic, Finland, Germany, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Russian Federation, Spain, Thailand, United Kingdom
Solvay Pharmaceuticals

Completed

SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease

Early Stage Parkinson Disease

United States, Australia, Czech Republic, Estonia, France, Germany, India, Italy, Lithuania, Malaysia, Netherlands, Poland, Portugal, South Africa, Spain, Taiwan, Thailand, United Kingdom

Clinical Trials on Movement; Abnormal, Involuntary in Portugal

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations